OBJECTIVE: The impact of different antiretroviral agents on the risk of developing or surviving CNS disease remains unknown. The aim of this study was to investigate whether using antiretroviral regimens with higher CNS penetration effectiveness (CPE) scores was associated with reduced incidence of CNS disease and improved survival in the UK Collaborative HIV Cohort (CHIC) Study. METHODS: Adults without previous CNS disease, who commenced combination antiretroviral therapy (cART) between 1996 and 2008, were included (n = 22,356). Initial and most recent cART CPE scores were calculated. CNS diseases were HIV encephalopathy (HIVe), progressive multifocal leukoencephalopathy (PML), cerebral toxoplasmosis (TOXO), and cryptococcal meningitis (CRYPTO). Incidence rates and overall survival were stratified by CPE score. A multivariable Poisson regression model was used to identify independent associations. RESULTS: The median (interquartile range) CPE score for initial cART regimen increased from 7 (5-8) in 1996-1997 to 9 (8-10) in 2000-2001 and subsequently declined to 6 (7-8) in 2006-2008. Differences in gender, HIV acquisition risk group, and ethnicity existed between CPE score strata. A total of 251 subjects were diagnosed with a CNS disease (HIVe 80; TOXO 59; CRYPTO 56; PML 54). CNS diseases occurred more frequently in subjects prescribed regimens with CPE scores ≤ 4, and less frequently in those with scores ≥ 10; however, these differences were nonsignificant. Initial and most recent cART CPE scores ≤ 4 were independently associated with increased risk of death. CONCLUSION: Clinical status at time of commencing cART influences antiretroviral selection and CPE score. This information should be considered when utilizing CPE scores for retrospective analyses.
OBJECTIVE: The impact of different antiretroviral agents on the risk of developing or surviving CNS disease remains unknown. The aim of this study was to investigate whether using antiretroviral regimens with higher CNS penetration effectiveness (CPE) scores was associated with reduced incidence of CNS disease and improved survival in the UK Collaborative HIV Cohort (CHIC) Study. METHODS: Adults without previous CNS disease, who commenced combination antiretroviral therapy (cART) between 1996 and 2008, were included (n = 22,356). Initial and most recent cART CPE scores were calculated. CNS diseases were HIV encephalopathy (HIVe), progressive multifocal leukoencephalopathy (PML), cerebral toxoplasmosis (TOXO), and cryptococcal meningitis (CRYPTO). Incidence rates and overall survival were stratified by CPE score. A multivariable Poisson regression model was used to identify independent associations. RESULTS: The median (interquartile range) CPE score for initial cART regimen increased from 7 (5-8) in 1996-1997 to 9 (8-10) in 2000-2001 and subsequently declined to 6 (7-8) in 2006-2008. Differences in gender, HIV acquisition risk group, and ethnicity existed between CPE score strata. A total of 251 subjects were diagnosed with a CNS disease (HIVe 80; TOXO 59; CRYPTO 56; PML 54). CNS diseases occurred more frequently in subjects prescribed regimens with CPE scores ≤ 4, and less frequently in those with scores ≥ 10; however, these differences were nonsignificant. Initial and most recent cART CPE scores ≤ 4 were independently associated with increased risk of death. CONCLUSION: Clinical status at time of commencing cART influences antiretroviral selection and CPE score. This information should be considered when utilizing CPE scores for retrospective analyses.
Authors: S Grabar; E Lanoy; C Allavena; M Mary-Krause; M Bentata; P Fischer; A Mahamat; C Rabaud; D Costagliola Journal: HIV Med Date: 2008-04 Impact factor: 3.180
Authors: A J Mocroft; J D Lundgren; A d'Armino Monforte; B Ledergerber; S E Barton; S Vella; C Katlama; J Gerstoft; C Pedersen; A N Phillips Journal: Int J Epidemiol Date: 1997-04 Impact factor: 7.196
Authors: R Mayeux; Y Stern; M X Tang; G Todak; K Marder; M Sano; M Richards; Z Stein; A A Ehrhardt; J M Gorman Journal: Neurology Date: 1993-01 Impact factor: 9.910
Authors: Christina M Marra; Yu Zhao; David B Clifford; Scott Letendre; Scott Evans; Katherine Henry; Ronald J Ellis; Benigno Rodriguez; Robert W Coombs; Giovanni Schifitto; Justin C McArthur; Kevin Robertson Journal: AIDS Date: 2009-07-17 Impact factor: 4.177
Authors: Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis Journal: Arch Neurol Date: 2008-01
Authors: Cecilia M Shikuma; Beau Nakamoto; Bruce Shiramizu; Chin-Yuan Liang; Victor DeGruttola; Kara Bennett; Robert Paul; Kalpana Kallianpur; Dominic Chow; Christina Gavegnano; Selwyn J Hurwitz; Raymond F Schinazi; Victor G Valcour Journal: Antivir Ther Date: 2012-09-28
Authors: Ankit Shah; Mohitkumar R Gangwani; Nitish S Chaudhari; Alexy Glazyrin; Hari K Bhat; Anil Kumar Journal: Neurotox Res Date: 2016-06-30 Impact factor: 3.911
Authors: Kenta Matsuda; Charles R Brown; Brian Foley; Robert Goeken; Sonya Whitted; Que Dang; Fan Wu; Ronald Plishka; Alicia Buckler-White; Vanessa M Hirsch Journal: J Virol Date: 2013-05-29 Impact factor: 5.103